8-K: Vaccinex Completes Last Patient Visit in Alzheimer's Disease Study, Awaits Key Results

Vaccinex has announced the completion of the last patient visit in its Phase 1b/2 SIGNAL-AD study of pepinemab for Alzheimer's disease, with key results expected in July.

Summary

• Vaccinex has completed the last patient visit in its SIGNAL-AD Phase 1b/2 study of pepinemab for Alzheimer's disease.
• The study is a randomized, placebo-controlled, double-blind trial.
• The company expects to lock the study database in June and report key outcomes later in July.
• Pepinemab targets astrocyte reactivity and neuroinflammation, which are believed to be key drivers of neurodegeneration in Alzheimer's disease.
• The study will assess the safety and tolerability of pepinemab, as well as its impact on brain metabolic activity and astrocyte reactivity.
• The study will also explore the impact of pepinemab on plasma levels of phosphorylated tau peptide (p-tau 217), a biomarker for tau tangles.
• Cognitive scales will be used as exploratory endpoints to evaluate potential treatment effects on cognitive decline.
• The study was funded in part by $4.75 million from the Alzheimer's Drug Discovery Foundation and a $0.75 million grant from the Alzheimer's Association.
• Pepinemab has been well-tolerated in clinical trials involving over 600 patients.

Sentiment

Score: 7

Explanation: The document is positive, highlighting the completion of a key study milestone and the potential of pepinemab. However, it also acknowledges the risks and uncertainties associated with clinical trials and regulatory approval.

Positives

• The completion of the last patient visit in the SIGNAL-AD study is a significant milestone.
• Pepinemab has shown a favorable safety profile in multiple clinical trials.
• The study is designed to assess key biomarkers of disease progression, including brain metabolic activity and astrocyte reactivity.
• The study is supported by funding from reputable organizations like the Alzheimer's Drug Discovery Foundation and the Alzheimer's Association.
• The company believes pepinemab could be an alternative or combination treatment to anti-Ab amyloid antibodies.

Negatives

• The document does not provide any negative information about the study or the company.
• The document does not provide any negative information about the drug.

Risks

• The study results are not yet available, and there is no guarantee that pepinemab will be effective in treating Alzheimer's disease.
• The company is dependent on its lead product candidate, pepinemab.
• There are risks associated with regulatory approval of the drug.
• The company could face delisting from Nasdaq if it fails to regain compliance with listing standards.

Future Outlook

The company anticipates reporting key outcomes from the SIGNAL-AD study in July and is exploring potential Phase 3 development in Huntington's disease. They are also evaluating pepinemab in combination with other drugs for cancer treatments.

Management Comments

• The company believes that the prevalence of AD and current concerns about the limitations of treatment with anti-Ab amyloid antibodies could make pepinemab, if approved, attractive as a potential alternative treatment or possibly for use in combination with anti-Ab to enhance the benefit to patients.
• The company believes that pepinemab appears to have been well-tolerated with a favorable safety profile in multiple clinical trials in different neurological and cancer indications.

Industry Context

The announcement comes amid growing interest in alternative treatments for Alzheimer's disease, particularly those that target mechanisms beyond amyloid plaques. The company positions pepinemab as a potential alternative or combination therapy to existing anti-amyloid treatments.

Comparison to Industry Standards

• The study is compared to the current standard of care which is anti-Ab amyloid antibodies such as Leqembi (Eisai and Biogen) and donanemab (Eli Lilly).
• The company is positioning pepinemab as a potential alternative or combination therapy to these treatments.
• The study is using biomarkers such as FDG-PET, GFAP, and p-tau 217 which are standard in the industry for assessing Alzheimer's disease progression.

Stakeholder Impact

• Shareholders may react positively to the completion of the study and the potential of pepinemab.
• Patients with Alzheimer's disease and their families may be hopeful about the potential of a new treatment option.
• Employees of Vaccinex may be motivated by the progress of the company's lead drug candidate.
• The company's collaborators, such as Merck, may be interested in the results of the study.

Next Steps

• The company will lock the study database in June.
• The company will report key outcomes of the SIGNAL-AD study in July.
• The company will continue to explore potential Phase 3 development in Huntington's disease.
• The company will continue to evaluate pepinemab in combination with other drugs for cancer treatments.

Key Dates

Keywords

pepinemab, Alzheimer's disease, SIGNAL-AD study, neurodegeneration, astrocyte reactivity, SEMA4D, clinical trial, biomarkers, neuroinflammation, Vaccinex